Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

The new drug – Quviviq (daridorexant) – has been approved by the European Commission for adults who have been suffering insomnia for at least three months and are experiencing "considerable ...

Orexin antagonists like Idorsia’s Quviviq (daridorexant), Eisai’s Dayvigo (lemborexant) and MSD’s Belsomra (suvorexant) are already approved for insomnia itself, by J&J believes that ...

Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment ...

Strengthening, aerobic, and combination exercise significantly lowered Global Pittsburgh Sleep Quality Index (GPSQI) in a network meta-analysis; GPSQI most effectively improved with strength ...